About Product

About NITTO DENKO

• Site Map
• Japanese
• Chinese
• Global

Nitto Denko and Kowa to Conduct Joint Development of Donepezil Hydrochloride-based Transdermal Drug Delivery Patches

2010.04.20

Japan's leading diversified materials company Nitto Denko Corporation (Nitto Denko) and Kowa Company, Ltd. (Kowa) have signed an agreement for the joint development of transdermal drug delivery patches based on the medicinal compound donepezil hydrochloride (DHC), an inhibitor of Alzheimer's disease symptoms, the companies announced today.

Under the agreement this time, the parties will conduct a joint development of DHC-based patches by utilizing Nitto Denko's technology platform for drug delivery patches, in order to respond to the hopes and expectations of the Alzheimer's disease patients, their families and care specialists.
Nitto Denko's business activities range over a broad range, from optical films for liquid crystal displays, automotive parts and seawater desalination membranes, to electronic materials and parts, environmental solutions and life science products.
Particularly in the field of transdermal drug delivery-type therapeutics, Nitto Denko had been ahead of the world in pursuing development work since the latter part of 1970's. With its R&D and production sites in Japan and in the U.S. where it has a specialized subsidiary Aveva Drug Delivery Systems, Inc. (ADS), Nitto Denko has established a superior production design technology for the therapeutic patches excelling in safety and stability, in addition to the technology for synthesizing adhesives optimally suited to controlled drug release into the human body.
Nitto Denko intends to continue with its endeavors to help improve people's quality of life through the development and commercialization of drug delivery patches for various types of medications.

Kowa Company, Ltd. is a privately-held multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various manufacturing and trading activities in the fields of pharmaceutical, life science, information technology, textiles, machinery and various consumer products.
Kowa started its pharmaceutical business in 1947. It has since built a strong presence in the Japanese prescription and OTC drug market and it is growing rapidly overseas. Kowa has established subsidiaries in Europe, US and China for the operation of its clinical development programs and the commercialization of its pharmaceutical products.
Kowa continues to be committed to expand its business in three core fields of pharmaceuticals - prescription, OTC and generic drugs - by integrating research and development of innovative products, manufacture of quality products, and appropriate promotion activities.

• Site Map
• Legal Information
• Privacy Policy